Gates Foundation’s $40m Incentivizes Cancer Specialist Immunocore To Develop TB, HIV Drugs

 
• By Lucie Ellis-Taitt
  
map
Gates Foundation Invests In Immunocore For Development Of New Drugs To Benefit Global Population
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business